Assura Plc

LSE:AGR Stock Report

Market Cap: UK£1.3b

Assura Valuation

Is AGR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AGR (£0.39) is trading above our estimate of fair value (£0.2)

Significantly Below Fair Value: AGR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGR?

Key metric: As AGR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AGR. This is calculated by dividing AGR's market cap by their current earnings.
What is AGR's PE Ratio?
PE Ratio19x
EarningsUK£66.10m
Market CapUK£1.26b

Price to Earnings Ratio vs Peers

How does AGR's PE Ratio compare to its peers?

The above table shows the PE ratio for AGR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.6x
THRL Target Healthcare REIT
7.2x3.4%UK£522.9m
CRT Care REIT
7.3x7.2%UK£348.1m
SAFE Safestore Holdings
6.2x-3.0%UK£1.6b
UKCM UK Commercial Property REIT
29.9xn/aUK£947.3m
AGR Assura
19x19.9%UK£1.3b

Price-To-Earnings vs Peers: AGR is expensive based on its Price-To-Earnings Ratio (19x) compared to the peer average (12.6x).

Price to Earnings Ratio vs Industry

How does AGR's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
AGR 19.0xIndustry Avg. 26.8xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AGR is good value based on its Price-To-Earnings Ratio (19x) compared to the Global Health Care REITs industry average (26.8x).

Price to Earnings Ratio vs Fair Ratio

What is AGR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19x
Fair PE Ratio18.4x

Price-To-Earnings vs Fair Ratio: AGR is expensive based on its Price-To-Earnings Ratio (19x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.39
UK£0.48
+25.0%
8.3%UK£0.55UK£0.40n/a9
Nov ’25UK£0.40
UK£0.49
+22.6%
6.4%UK£0.55UK£0.45n/a9
Oct ’25UK£0.43
UK£0.49
+14.4%
6.4%UK£0.55UK£0.45n/a9
Sep ’25UK£0.42
UK£0.49
+17.8%
5.8%UK£0.55UK£0.45n/a9
Aug ’25UK£0.42
UK£0.50
+20.0%
5.9%UK£0.55UK£0.45n/a9
Jul ’25UK£0.40
UK£0.50
+24.1%
5.9%UK£0.55UK£0.45n/a9
Jun ’25UK£0.41
UK£0.50
+20.7%
5.2%UK£0.55UK£0.45n/a10
May ’25UK£0.41
UK£0.51
+24.0%
4.0%UK£0.55UK£0.48n/a10
Apr ’25UK£0.42
UK£0.51
+19.6%
4.0%UK£0.55UK£0.48n/a10
Mar ’25UK£0.42
UK£0.51
+21.4%
4.3%UK£0.55UK£0.48n/a10
Feb ’25UK£0.43
UK£0.51
+17.8%
4.8%UK£0.55UK£0.48n/a10
Jan ’25UK£0.48
UK£0.52
+8.1%
6.3%UK£0.59UK£0.48n/a10
Dec ’24UK£0.45
UK£0.52
+14.8%
6.3%UK£0.59UK£0.48n/a10
Nov ’24UK£0.41
UK£0.52
+26.1%
7.1%UK£0.59UK£0.48UK£0.4010
Oct ’24UK£0.42
UK£0.54
+26.7%
7.4%UK£0.59UK£0.48UK£0.439
Sep ’24UK£0.45
UK£0.54
+19.4%
6.5%UK£0.59UK£0.49UK£0.429
Aug ’24UK£0.47
UK£0.56
+19.5%
12.7%UK£0.75UK£0.49UK£0.4210
Jul ’24UK£0.45
UK£0.59
+30.2%
13.9%UK£0.75UK£0.52UK£0.4010
Jun ’24UK£0.48
UK£0.60
+25.2%
13.8%UK£0.75UK£0.52UK£0.4110
May ’24UK£0.51
UK£0.61
+19.8%
13.7%UK£0.75UK£0.50UK£0.4110
Apr ’24UK£0.49
UK£0.61
+24.8%
13.7%UK£0.75UK£0.50UK£0.4210
Mar ’24UK£0.51
UK£0.61
+20.6%
12.8%UK£0.75UK£0.50UK£0.4211
Feb ’24UK£0.55
UK£0.63
+14.4%
11.2%UK£0.75UK£0.55UK£0.4311
Jan ’24UK£0.55
UK£0.65
+19.3%
11.7%UK£0.77UK£0.55UK£0.4811
Dec ’23UK£0.55
UK£0.66
+20.6%
11.7%UK£0.77UK£0.55UK£0.4511
Nov ’23UK£0.57
UK£0.69
+21.3%
11.2%UK£0.77UK£0.53UK£0.4111

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Cofinimmo

€2.1b

Cofinimmo has been acquiring, developing and managing rental properties for 40 years.

0J3X

€56.26

7D

-1.6%

1Y

-13.1%

Xior Student Housing

€1.3b

Xior Student Housing NV is the first Belgian public regulated real estate company (RREC) specialising in the student housing segment in Belgium, the Netherlands, Spain, Portugal, Germany, Poland, Denmark and Sweden.

0RD8

€30.80

7D

1.8%

1Y

-0.9%

Care REIT

UK£348.1m

Impact Healthcare REIT plc acquires, renovates, extends and redevelops high quality healthcare real estate assets in the UK and lets these assets on long-term full repairing and insuring leases to high-quality established healthcare operators which offer good quality care, under leases which provide the Company with attractive levels of rent cover.

CRT

UK£0.84

7D

2.9%

1Y

-1.5%